STAT

OCTOBER 10, 2024

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.

Packaging 297

Packaging Diabetes Pharmaceutical Companies Pharmaceutical Companies 297

STAT

JULY 23, 2024

That lame duck period might be an opportune time for Congress to pass a health care legislative package that includes PBM reforms, though it’s difficult to predict what will happen following the elections. Continue to STAT+ to read the full story…

Packaging 346

Packaging Drug Pricing 346

STAT

SEPTEMBER 19, 2023

About last night… House leadership last night canceled a scheduled vote on a health care package that included transparency requirements for hospitals and insurers, reforms to some PBM practices, and a small site-neutral payment policy for administering drugs, Rachel writes.

Packaging 277

Packaging Hospitals Drug Pricing 277

STAT

OCTOBER 16, 2023

The lawsuit was filed in response to a state law that was passed in August and requires health insurers that provide coverage for these injectors to cap out-of-pocket costs to $60 for a package of two injectors. At the same time, the law — which goes into effect Jan.

Packaging 324

Packaging Drug Pricing 324

STAT

SEPTEMBER 1, 2023

Simply put, a drug company combines two or more medicines in a package deal for health plans and pharmacy benefit managers, which determine lists of medicines that are covered by insurance. Regulators were concerned about a practice known as bundling.

Packaging 296

Packaging Drug Pricing 296

STAT

OCTOBER 17, 2024

Eli Lilly, a chief Novo rival, uses Catalent for filling and packaging, and has complained openly about the deal. Continue to STAT+ to read the full story…

Diabetes 283

Diabetes Packaging Drug Pricing Drug Development 283

STAT

MAY 10, 2023

The hearing sets up a debate by the same committee Thursday over a package of bills aimed at PBM reform. Continue to STAT+ to read the full story…

Packaging 255

Packaging Drug Pricing 255

STAT

JULY 24, 2023

The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.

Packaging 246

Packaging Drug Pricing Hospitals 246

Safe Biologics

NOVEMBER 12, 2023

6 would prevent the HHS Secretary from requiring a switching study as part of the data package to receive the interchangeable designation. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. However, S.6 ASBM surveys of U.S.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Pharmaceutical Technology

NOVEMBER 21, 2022

One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions. This trend continues as it estimated that the FY2022 price revision led to an average price reduction of 4% to 5% for major drug makers.

Drug Pricing 69

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 69

Safe Biologics

DECEMBER 3, 2023

The most recen t of the webinars, hosted July 29th, examined the negative impact of the Inflation Reducation Act’s Medicare drug price setting provisions. The guidance removed the interchangeability statement from the product label/package insert of interchangeable biosimilars.

Biosimilars 130

Biosimilars Labelling Drug Pricing Packaging 130

Safe Biologics

DECEMBER 6, 2023

REMINDER: FDA Draft Guidance Would Remove Interchangeability Statement from Interchangeable Biosimilars Comments Due November 17th On September 15th, the Food and Drug Administration (FDA) released draft guidance removing the interchangeability statement from the product label/package insert. ASBM surveys of U.S. However, S.6

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

Pharmaceutical Technology

NOVEMBER 21, 2022

One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions. This trend continues as it estimated that the FY2022 price revision led to an average price reduction of 4% to 5% for major drug makers.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

Pharmaceutical Technology

MARCH 10, 2023

Consequentially, the five-year average price trend in Lebanon for all medicines has increased to 1,123%. GlobalData reviews the key events leading up to these current price trends in Lebanon. As this reduction of subsidies coincided with the weakening of the Lebanese pound, it resulted in further heavy price increases.

Drug Pricing 52

Drug Pricing Packaging 52

Proxsys Rx

OCTOBER 6, 2022

That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drug pricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package.

Hospitals 52

Hospitals Drug Pricing Communication Pharmaceutical Manufacturing 52

European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. It is too early to say because we have not seen the whole package of measures yet.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

European Pharmaceutical Review

DECEMBER 26, 2023

Advanced inducible systems to better regulate the expression of certain genes will improve the generation of packaging and producer cell clones, giving companies more control over gene expression for improved safety as well as efficiency. million for Hemgenix [AAV5-hFIX-Padua]).

Drug Pricing 98

Drug Pricing Packaging Vaccines Drug Development 98

HealthPartners

MAY 6, 2021

Drug rebates can distort true drug pricing A small but growing number of employers see rebates as a pricing distortion. When medication volume is incentivized by the drug manufacturer, how motivated will the PBM be to stop wasteful use of drugs?

Mail-Order Pharmacies 52

Mail-Order Pharmacies Drug Pricing Packaging 52

Proxsys Rx

APRIL 19, 2024

Two potential 340B developments for 2024 In an article dated January 5, the subscriber-only website 340B Report projected that “In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package.”

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52

NY Times

JULY 15, 2022

Only two provisions in a once-sprawling social spending package have survived; they would lower prescription drug prices in Medicare and insurance premiums for millions of Americans.

Drug Pricing 62

Drug Pricing Packaging 62

HealthPartners

JULY 21, 2021

This integrated approach keeps everything together in one package that is coordinated by your primary medical health plan vendor. For example, members can compare drug prices at pharmacies or find a network provider. What does it mean to carve in pharmacy? Why should employers care about transparency in pharmacy benefits?

Biosimilars 52

Biosimilars Specialty Pharmacies Mail-Order Pharmacies Health Insurance Companies 52

Proxsys Rx

JANUARY 12, 2024

Two potential 340B developments for 2024 In an article dated January 5, the subscriber-only website 340B Report projected that “In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package.”

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52

STAT

OCTOBER 13, 2023

And lawmakers are always eager to brag to voters that they took action against high prescription drug prices. CVS Caremark, Express Scripts, and Optum Rx face new transparency rules and restrictions on how they make money under a legislative package. Continue to STAT+ to read the full story…

Drug Pricing 267

Drug Pricing Packaging 267

STAT

SEPTEMBER 23, 2022

… The White House is pitching an added benefit to the recent drug-pricing reform package: lower cancer death rates , STAT explains. A  A new analysis by the Council of Economic Advisers focused on a provision that caps Medicare out-of-pocket costs for pharmacy drugs at $2,000 a year, starting in 2025.

Drug Pricing 240

Drug Pricing Packaging 240

Putting Patients First Blog

AUGUST 28, 2023

Appropriations The most pressing deadline facing Congress as they return from August recess is passing a federal spending package. This bill aims to delink the compensation of PBMs from drug prices. Below is a summary of key items to keep a lookout for in the coming months.

Packaging 52

Packaging Drug Pricing 52

Putting Patients First Blog

DECEMBER 13, 2023

In response, a debt ceiling package was signed without Medicaid work requirements, symbolizing the power of patient advocates’ voices. In submitted comments , the NHC commended CMS for its initiatives to reduce patient burdens, while also emphasizing the importance of continued monitoring and oversight to strengthen the program.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Drug Pricing Packaging 52

STAT

DECEMBER 16, 2024

Lawmakers agreed to extend telehealth flexibilities, fund public health programs, and enact these major PBM changes as part of a government funding package they are planning to pass before the end of the year, according to four health care industry sources and two congressional aides.   Continue to STAT+ to read the full story…

Packaging 320

Packaging Drug Pricing 320

STAT

FEBRUARY 10, 2023

WASHINGTON — Generic drugmakers lobbied hard against Democrats’ new law empowering Medicare to negotiate prescription drug prices. Now that the changes are law, however, industry experts and lobbyists acknowledge the package is more of a mixed bag for generics makers like Teva and Sandoz, not an existential threat.

Drug Pricing 245

Drug Pricing Generic Medicine Packaging 245

STAT

SEPTEMBER 19, 2022

WASHINGTON — One of Washington’s most prominent drug pricing patient groups is tapping an advocate who has fought for access to medicines for nearly two decades as its new leader. Continue to STAT+ to read the full story…

Drug Pricing 246

Drug Pricing Packaging 246

STAT

FEBRUARY 26, 2024

WASHINGTON — Congress will not move forward with a controversial policy to equalize certain Medicare payments to hospitals and physicians’ offices in an upcoming government funding package, five lobbyists and sources following the talks told STAT. The delay is a win for hospitals, which have adamantly lobbied against the policy.

Hospitals 306

Hospitals Packaging Drug Pricing 306

STAT

JULY 25, 2023

The company had said in April it would pause or discontinue at least four studies of experimental drugs to focus on more lucrative options including the Leqembi launch and trim costs.

Packaging 244

Packaging Hospitals Drug Pricing 244

STAT

SEPTEMBER 23, 2022

WASHINGTON — The White House is pitching an added benefit to Democrats’ recent drug pricing reform package: lower cancer death rates. Over 449,000 current Medicare enrollees with a prior cancer diagnosis would save an average of nearly $1,600 per year on prescription drugs because of the out-of-pocket cap.

Drug Pricing 258

Drug Pricing Packaging 258

NY Times

SEPTEMBER 14, 2021

trillion package of tax increases on income, not wealth. Progressive senators pushed back hard on the decision by senior Democrats to focus a $2.1

Drug Pricing 53

Drug Pricing Packaging 53

STAT

DECEMBER 17, 2024

Lawmakers agreed to extend telehealth flexibilities, fund public health programs, and enact these major changes as part of a government funding package they are planning to pass before the end of the year. The language of the government funding package has not been publicly released, and could still change.

Packaging 132

Packaging Hospitals Drug Pricing Pharmaceutical Companies 132

STAT

DECEMBER 19, 2024

Congressional leaders had reached a deal to rein in prescription drug middlemen earlier this week, but the larger package it was tacked onto fell apart following backlash from conservatives and top advisers to President-elect Trump.

Packaging 339

Packaging Hospitals Drug Pricing 339

NY Times

JULY 6, 2022

The drug-pricing plan was negotiated with Senator Joe Manchin III of West Virginia, but Democrats remain short of agreement on what else would be included in any domestic policy package.

Drug Pricing 66

Drug Pricing Packaging 66

STAT

MARCH 7, 2023

 The plan would give the administration authority to negotiate what price the federal government pays for more drugs than the limited number approved as part of Democrats’ legislative package last year, while also speeding up the process for negotiations.

Drug Pricing 245

Drug Pricing Packaging 245